Bradford A. Zakes
Mr. Zakes has served as Cerevast’s President and Chief Executive Officer since its inception in September 2009. Previously, he served as President and CEO of ImaRx Therapeutics, Inc. a publicly traded biopharmaceutical company focused on the development of microsphere technology and biotherapeutics. Mr. Zakes has spent over 25 years in various segments of the pharmaceutical, biotechnology and med-tech industries. Following his career as a commissioned officer in the United States Army, Mr. Zakes held positions at Hazleton Laboratories, Glaxo (currently Glaxo Smithkline) and ICOS Corporation. While at Glaxo, Mr. Zakes played an active role in the clinical development of Zantac and managed the sNDA program for the approval of Serevent for chronic obstructive pulmonary disease. Mr. Zakes holds a BS degree in Biology from Oregon State University, an MS degree in Toxicology from the American University and received his MBA from Duke University’s Fuqua School of Business. Additionally, Mr. Zakes serves on the Board of Directors for the Biotechnology Industry Organization (BIO) as well as the Emerging Company Section Governing Body and the Standing Committees on International Affairs and Budget and Audit for BIO.